Association of Vascular Risk Factors With β-Amyloid Peptide and Tau Burdens in Cognitively Unimpaired Individuals and Its Interaction With Vascular Medication Use
| Title: | Association of Vascular Risk Factors With β-Amyloid Peptide and Tau Burdens in Cognitively Unimpaired Individuals and Its Interaction With Vascular Medication Use |
|---|---|
| Authors: | Theresa Köbe; Julie Gonneaud; Alexa Pichet Binette; Pierre-Francois Meyer; Melissa McSweeney; Pedro Rosa-Neto; John C. S. Breitner; Judes Poirier; Sylvia Villeneuve; Paul Aisen; Elena Anthal; Melissa Appleby; Gulebru Ayranci; Pierre Bellec; Véronique D. Bohbot; Leopoldina Carmo; Mallar Chakravarty; Laksanun Cheewakriengkrai; Louis Collins; Leslie-Ann Daoust; Marina Dauar-Tedeschi; Doris Dea; Clement Debacker; Guerda Duclair; Marianne Dufour; Rana El-Khoury; Pierre Etienne; Alan Evans; Fabiola Ferdinand; David Fontaine; Josee Frappier; Joanne Frenette; Guylaine Gagne; Serge Gauthier; Valerie Gervais; Renuka Giles; Renee Gordon; Rick Hoge; Yasser Ruda-Medina; Justin Kat; Christina Kazazian; Anne Labonté; Marie-Élyse Lafaille-Magnan; Tanya Lee; Illana Leppert; Cecile Madjar; Laura Mahar; Jean-Robert Malta; Ginette Mayrand; Justin Miron; Nathalie Nilsson; Pierre Orban; Tharick A. Pascoal; Mirela Petkova; Cynthia Picard; Morteza Pishnamazi; Galina Pogossova; Judes Pokier; Jens Pruessner; M. Natasha Rajah; Melissa Savard; Shirin Tabrizi; Angela Tam; Christine Tardif; Eduard Teigner; Louise Theroux; Jennifer Tremblay-Mercier; Miranda Tuwaig; Isabelle Vallee; Vinod Venugopalan; Sander C. J. Verfaillie; Karen Wan; Alan Barkun; Claudio Cuello; Mahsa Dadar; Samir Das; Mark Eisenberg; Vladimir Fonov; Penelope Kostopoulos; Claude Lepage; Gerhard Maultaup; Lisa-Marie Munter; Pierre Rioux; Paule-Joanne Toussaint; Jacob Vogel; Thomas Beaudry; Christophe Bedetti; Fatiha Benbouhoud; Charles Edouard Carrier; Blandine Courcot; Doris Couture; Rene Desautels; Sylvie Dubuc; Sarah Farzin; Anne-Marie Faubert; David Maillet; Axel Mathieu; Sulantha Mathotaarachchi; Diane Michaud; 24 Others |
| Publication Year: | 2023 |
| Subject Terms: | Neurosciences; biological and chemical aspects; n.e.c; alzheimer-disease neuropathology; coronary-heart-disease; pulse pressure; blood-pressure; cholesterol; deposition; dementia; pet; neurodegeneration; hypertension |
| Description: | Importance: Vascular risk factors are associated with increased risk of Alzheimer disease (AD), but it is unclear whether there is a direct association of these risk factors with AD pathogenesis. Objectives: To assess the associations of vascular risk factors with AD pathogenesis in asymptomatic individuals, and to test whether this association is moderated among individuals who use vascular medications. Design, setting, and participants: This cross-sectional study used data from the Presymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer Disease (PREVENT-AD) cohort of cognitively unimpaired individuals aged 55 to 82 years with a parental or multiple-sibling history of sporadic AD, who were recruited via advertisement from the greater Montreal, Quebec, Canada, metropolitan area. Participants were enrolled between September 9, 2011, to May, 3, 2017, and stratified by use vs no use of vascular medications. Data were analyzed July 1, 2018, to April 5, 2019. Main outcomes and measures: Principal analyses investigated associations of total, high-density lipoprotein, and low-density lipoprotein cholesterol levels, systolic and diastolic blood pressure, pulse pressure, and a combined vascular risk score (measured using the Framingham Coronary Risk Profile) with global β-amyloid peptide (Aβ) and entorhinal tau burden as measured by positron emission tomography (PET). Potential moderating associations of use of vascular medications with these associations were examined. Secondary similar analyses considered cerebrospinal fluid (CSF) Aβ1-42 and phosphorylated tau levels. Results: Among 215 participants (mean [SD] age, 62.3 [5.0] years; 161 [74.8%] women), 120 participants underwent PET, including 75 participants (62.5%) who were not using vascular medications, and 162 participants underwent CSF assessment, including 113 participants (69.8%) who were not using vascular medications. There was an overlap of 67 participants who underwent PET and CSF assessment. Interaction analyses showed that among ... |
| Document Type: | article in journal/newspaper |
| Language: | unknown |
| DOI: | 10.32920/24435394.v1 |
| Availability: | https://doi.org/10.32920/24435394.v1; https://figshare.com/articles/journal_contribution/Association_of_Vascular_Risk_Factors_With_-Amyloid_Peptide_and_Tau_Burdens_in_Cognitively_Unimpaired_Individuals_and_Its_Interaction_With_Vascular_Medication_Use/24435394 |
| Rights: | CC BY 4.0 |
| Accession Number: | edsbas.8FA833A5 |
| Database: | BASE |